Maravai LifeSciences (MRVI)
(Delayed Data from NSDQ)
$10.70 USD
+0.17 (1.61%)
Updated May 14, 2024 04:00 PM ET
After-Market: $10.71 +0.01 (0.09%) 4:18 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Maravai LifeSciences Holdings, Inc. (MRVI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$10.15 | $15.00 | $6.50 | -3.61% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Maravai LifeSciences Holdings, Inc. comes to $10.15. The forecasts range from a low of $6.50 to a high of $15.00. The average price target represents a decline of 3.61% from the last closing price of $10.53.
Analyst Price Targets (10)
Broker Rating
Maravai LifeSciences Holdings, Inc. currently has an average brokerage recommendation (ABR) of 1.63 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.63 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, seven are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 58.33% and 16.67% of all recommendations. A month ago, Strong Buy made up 58.33%, while Buy represented 16.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 6 | 6 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.63 | 1.63 | 1.63 | 1.68 | 1.68 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/9/2024 | Robert W. Baird & Co. | Catherine W Schulte | Strong Buy | Strong Buy |
4/10/2024 | Craig-Hallum | Christian D Schwab | Not Available | Strong Buy |
11/8/2023 | William Blair | Matt Larew | Strong Buy | Strong Buy |
11/7/2023 | KeyBanc Capital Markets | Paul Knight | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.63 |
ABR (Last week) | 1.63 |
# of Recs in ABR | 12 |
Average Target Price | $10.15 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 142 of 252 |
Current Quarter EPS Est: | 0.00 |